Evidence map›Paper›PMID 38817890›Full record

ArticleFrontiers in oncology2024

Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer - a retrospective analysis.

Gudrun Piringer, Florian Ponholzer, Josef Thaler, Thomas Bachleitner-Hofmann, Holger Rumpold, Alexander de Vries, Lukas Weiss, Richard Greil, Michael Gnant, Dietmar Öfner

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gudrun Piringer *Department of Hematology and Oncology, Kepler University Hospital, Linz, Austria.
Florian Ponholzer *Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Josef ThalerDepartment of Internal Medicine IV, Wels-Grieskirchen Medical Hospital, Wels, Austria.
Thomas Bachleitner-HofmannDivision of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.
Holger RumpoldMedical Faculty, Johannes Kepler University Linz, Linz, Austria.
Alexander de VriesDepartment of Radiotherapy and Radio-Oncology, Feldkirch Hospital, Feldkirch, Austria.
Lukas Weiss3rd Medical Department of Internal Medicine III, Paracelsus Medical University, Salzburg, Austria.
Richard Greil3rd Medical Department of Internal Medicine III, Paracelsus Medical University, Salzburg, Austria.
Michael GnantComprehensive Cancer Center, Medical University, Vienna, Austria.
Dietmar ÖfnerDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The aim of this retrospective analysis was to determine if the response to preoperative radio(chemo)therapy is predictive for survival among patients with locally advanced rectal cancer and may act as a potential surrogate endpoint for disease free survival and overall survival. Results: Eight hundred seventy-eight patients from five centers were analyzed. There were 304 women and 574 men; the median age was 64.7 years. 77.6% and 22.4% of patients received neoadjuvant radiochemotherapy or short-course radiotherapy, resulting in a pathological complete response in 7.3%. T-downstaging and N-downstaging occurred in 50.5% and 37% of patients after neoadjuvant therapy. In patients with T-downstaging, the 10-year DFS and 10-year OS were 64.8% and 66.8% compared to 37.1% and 45.9% in patients without T-downstaging. N-downstaging resulted in 10-year DFS and 10-year OS in 56.2% and 62.5% compared to 47.3% and 52.3% without N-downstaging. Based on routinely evaluated clinical parameters, an absolute risk prediction calculator was generated for 5-year disease-free survival, and 5-year overall survival. Conclusion: T-downstaging and N-downstaging after neoadjuvant radiochemotherapy or short-course radiotherapy resulted in better DFS and OS compared to patients without response. Based on clinical parameters, 5-year DFS, and 5-year OS can be predicted using a prediction calculator.

Indexed as

locally advanced rectal cancerNdownstagingneoadjuvant radiochemotherapyprediction of survivalT-downstaging

Identifiers

PMID38817890
PMCPMC11137682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.